StoryRegulatory
LivaNova initiates CMS reconsideration for VNS Therapy in treatment-resistant depression
LivaNova petitioned CMS to reconsider national Medicare coverage for VNS Therapy in patients with unipolar treatment-resistant depression, supported by 24-month results from the RECOVER trial showing 51.6% of patients achieved clinically meaningful benefit. The company cited five peer-reviewed publications from the trial in leading medical journals.